Publications and Presentations

Publications and Presentations

HFB200301

American Society of Clinical Oncology | Poster | April 27, 2022

Phase I study of HFB200301, a First-in-Class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS™) Phase I study of HFB200301, a First-in-Class TNFR2 agonist monoclonal antibody in patients with solid tumors selected via Drug Intelligent Science (DIS™)

American Association for Cancer Research | Presentation | April 12, 2021

Mechanism of Action and Biomarker Strategy for HFB200301, an Anti-TNFR2 Agonist Antibody for the Treatment of Cancer

American Association for Cancer Research | Poster | July 03, 2020

Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment Discovery and characterization of novel TNFR2 antibodies to modulate T cell activities in immunosuppressive environment

HFB301001

European Society for Medical Oncology Congress | Poster | September 12, 2022

Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS™) Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS™)

American Association for Cancer Research | Presentation | April 12, 2021

Clinical approach and biomarker strategy for HFB301001, a novel OX40 agonistic antibody

American Association for Cancer Research | Poster | July 03, 2020

HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy HFB301001, a novel OX40 agonistic antibody with a unique pharmacological profile and innovative biomarker strategy

HFB200603

American Association for Cancer Research | Poster | April 13, 2022

HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment HFB200603, a novel anti-BTLA monoclonal antibody that provides therapeutic potential for immune escape and synergizes with anti-PD-1 treatment

HFB200902

American Association for Cancer Research | Presentation | April 12, 2021

HFB9-2, a novel Galectin 9 neutralizing antibody for the treatment of AML and other cancers

Nature Scientific | Publication | March 04, 2021

Serial transplantation unmasks galectin‐9 contribution to tumor immune escape in the MB49 murine model Serial transplantation unmasks galectin‐9 contribution to tumor immune escape in the MB49 murine model

American Association for Cancer Research | Poster | July 03, 2020

HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment HFB9-2, a novel Galectin-9 neutralizing antibody to reverse immune suppression in the tumor microenvironment

HFB101110

American Association for Cancer Research | Poster | April 18, 2022

Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors Targeting regulatory T cells with HFB101110, a novel anti-human CCR8 antibody for the treatment of solid tumors

HFB100204

American Association for Cancer Research | Presentation | April 12, 2021

Discovery and characterization of a novel anti-human CXCR5 antibody for the treatment of B cell lymphomas

Platform

American Association for Cancer Research | Poster | April 08, 2022

Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization Discovery of predictive biomarkers of response to T cell-targeting biologics using ex vivo single-cell profiling coupled with TCR clonotype characterization

Science Advances | Publication | June 11, 2021

High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics High-throughput functional screening for next-generation cancer immunotherapy using droplet-based microfluidics

American Association for Cancer Research | Presentation | September 17, 2020

HiFiBiO Therapeutics Presents Novel Approach to Patient Stratification Demonstrating DIS™ Single-Cell Platform at 2020 AACR Tumor Heterogeneity Conference

Nature Biotechnology | Publication | March 30, 2020

High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics High-throughput single-cell activity-based screening and sequencing of antibodies using droplet microfluidics

Nature Genetics | Publication | May 31, 2019

High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer High-throughput single-cell ChIP-seq identifies heterogeneity of chromatin states in breast cancer

Nature Biotechnology | Publication | September 11, 2017

Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring Single-cell deep phenotyping of IgG-secreting cells for high-resolution immune monitoring

HiFiBio, Paris | Poster | November 13, 2016

Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study Antibody Discovery by Deep Mining of Immune Repertoires: A demonstration of the HiFiBiO CelliGO™ Platform versatility and robustness with Tetanus Toxoid antigen as a case study

Other Programs

Frontiers in Pharmacology | Publication | May 23, 2023

Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study Safety, tolerability, pharmacokinetics, and immunogenicity of an anti-SARS-CoV-2 monoclonal antibody HFB30132A after single dose intravenous administration in healthy Chinese subjects: a phase 1, randomized, double-blind, placebo-controlled study

Science | Publication | October 22, 2021

Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: A global consortium study

Nature Communications | Publication | May 11, 2021

A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes A SARS-CoV-2 neutralizing antibody with extensive Spike binding coverage and modified for optimal therapeutic outcomes

Biotech2050 | Podcast | June 14, 2023 | 30m 57s

CEO Liang Schweizer speaks with Rahul Chaturvedi on the Biotech2050 Podcast about her journey from scientist to first-time CEO and how HiFiBiO is improving the success rate of immunotherapies by leveraging unprecedented single-cell level insights into patient heterogeneity.

Life Science Success Podcast | Podcast | January 5, 2023 | 28m 18s

CEO Liang Schweizer spoke with Don Davis on the Life Science Success Podcast about her professional journey and how HiFiBiO is using DIS® to accelerate the delivery of precision immunotherapies to patients.

Dealmakers Show | Podcast | September 9, 2022 | 35m

CEO Liang Schweizer appeared on the Dealmakers Show by Alejandro Cremades to share the advantages of starting global, managing remote working in drug discovery, building a strong global culture, and how she raised over $180 million in funding.

Talking Biotech Podcast | Podcast | August 20, 2022 | 52m 03s

CEO Liang Schweizer shared her thoughts and experience with Kevin Folta on the Talking Biotech podcast on how HiFiBiO is using single-cells and microfluidics to identify new antibodies, as well as what could guide application of the most effective treatments.

Lioness Magazine Interview | Interview | March 11, 2021 | 35m 23s

CEO Liang Schweizer shared with Lioness Magazine how HiFiBiO combines biological expertise with single-cell profiling technologies to advance antibody drugs. She also highlighted the importance of community service and mentorship to her successes.

Genialis Podcast | Podcast | February 26, 2021 | 51m 07s

CEO Liang Schweizer spoke with Rafael Rosengarten from Genialis about Drug Intelligence Science (DIS®) that combines data intelligence with single-cell science to achieve optimal outcomes for all stages of drug discovery and development.

PharmaBoardRoom Article | Article | February 17, 2021

CEO Liang Schweizer introduced HiFiBiO Therapeutics, the main advantages of the company’s unique single-cell technology platform, its open innovation approach, experience with capital markets, and advice for other biotech leaders.

BioBoss Podcast | Podcast | September 29, 2019 | 48m

CEO Liang Schweizer interviewed with John Simboli on the BioBoss podcast to share her perspectives on biotech leadership and highlight the uniqueness of HiFiBiO’s single-cell driven Drug Intelligence Science (DIS®) approach and highly diverse teams.